VYNE Therapeutics
VYNE
59 hedge funds and large institutions have $139M invested in VYNE Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 7 closing their positions.
103% more capital invested
Capital invested by funds: $68.4M → $139M (+$70.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more funds holding
Funds holding: 56 → 59 (+3)
0.06% more ownership
Funds ownership: 0.99% → 1.06% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$6.21M |
| 2 |
O
OrbiMed
New York
|
+$4.23M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 5 |
DM
Deerfield Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.23M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$1.07M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$982K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$703K |
| 5 |
JP Morgan Chase
New York
|
-$564K |
VYNE Hedge Fund Activity: Q1 2019 in Review
59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2019, worth a combined $139M — up 103% from $68.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new VYNE positions and 7 closed out — a net gain of 3 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was First Manhattan, adding an estimated $6.21M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.23M sold.
- 59 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2019, up from 56 in Q4 2018.
- Funds reported $139M of VYNE Therapeutics stock for Q1 2019, up 103% quarter-over-quarter.
- 10 funds opened new VYNE Therapeutics positions in Q1 2019 and 7 closed out, a net change of +3 holders.
- The largest VYNE Therapeutics buyer in Q1 2019 was First Manhattan, an estimated $6.21M added.
- The largest VYNE Therapeutics seller in Q1 2019 was Novo Holdings A/S, an estimated $5.23M sold.
Based on aggregated 13F filings for Q1 2019.